At the news
? NEUTRALIMPACT 3/10 CLUSTER filed Aug 5, 2026 at 16:02 ET
Two Pfizer directors, Ronald Blaylock and Mortimer Buckley, made open-market purchases totaling ~$1.96M on August 5, 2026, two days after the company reported a Q2 2026 adjusted EPS beat of $0.77 (+12.9% vs consensus) and raised full-year revenue guidance. The CEO's grant of 24 shares is a routine non-cash award. While the director purchases are a modest positive signal, the total dollar value is only ~0.001% of Pfizer's $147B market cap, making it trivial in scale and unlikely to move the stock.
- Two directors purchased ~$1.96M in open-market stock on August 5, 2026, at ~$25.50/share.
- Purchases occurred two days after Pfizer reported Q2 2026 adjusted EPS of $0.77 (12.9% beat) and raised FY2026 revenue guidance by $500M.
- Total insider purchases represent ~0.001% of Pfizer's $147.1B market cap, trivial in scale.
- CEO Albert Bourla received a non-cash grant of 24 shares worth $600, no economic signal.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access